Security
Belite Bio, Inc American Depositary Shares · BLTE
BLTENASDAQotherCurrentCIK 1889109Updated Oct 3, 2026
Name history
BELITE BIO, INC · through Oct 1, 2026
BLTE price & chart
Loading TradingView…
NASDAQ:BLTE on TradingView ↗In the news
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 ↗
Seeking Alpha
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Belite Bio On Track For A Potential Blockbuster Launch In 2027 ↗
Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 - Slideshow ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 780,556,000Source | 152,132,000Source | 94,642,000Source | 44,273,000Source |
| Property, Plant and Equipment, NetUSD | 344,000Source | 444,000Source | 490,000Source | 541,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 19,000Source | 31,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 352,932,000Source | 31,677,000Source | 88,157,000Source | 42,089,000Source |
| Assets, CurrentUSD | 494,272,000Source | 147,073,000Source | 89,940,000Source | 42,807,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,150,000Source | 1,349,000Source | 947,000Source | 716,000Source |
| Operating Lease, Right-of-Use AssetUSD | 433,000Source | 521,000Source | 811,000Source | 806,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 10,070,000Source | 6,311,000Source | 4,211,000Source | 2,772,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 4,000Source | 3,000Source | 3,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 956,276,000Source | 254,125,000Source | 162,305,000Source | 81,761,000Source |
| Retained Earnings (Accumulated Deficit)USD | -185,258,000Source | -107,647,000Source | -71,503,000Source | -39,871,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -536,000Source | -660,000Source | -374,000Source | -392,000Source |
| Stockholders' Equity Attributable to ParentUSD | 770,486,000Source | 145,821,000Source | 90,431,000Source | 41,501,000Source |
| Liabilities and EquityUSD | 780,556,000Source | 152,132,000Source | 94,642,000Source | 44,273,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,882,000Source | 6,050,000Source | 3,633,000Source | 2,104,000Source |
| Operating Lease, Liability, CurrentUSD | 241,000Source | 276,000Source | 308,000Source | 198,000Source |
| Operating Lease, Liability, NoncurrentUSD | 188,000Source | 261,000Source | 578,000Source | 668,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,636,000Source | 5,761,000Source | 3,325,000Source | 1,906,000Source |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -77,611,000Source | -36,144,000Source | -31,632,000Source | -12,648,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 38,919,000Source | 8,987,000Source | 3,823,000Source | 1,483,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -36,988,000Source | -29,234,000Source | -29,837,000Source | -11,458,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -305,107,000Source | -110,572,000Source | -63,000Source | -394,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 71,000Source | 116,000Source | 63,000Source | 394,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 663,233,000Source | 83,595,000Source | 75,959,000Source | 36,963,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 321,255,000Source | -56,480,000Source | 46,068,000Source | 24,745,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 352,932,000Source | 31,677,000Source | 88,157,000Source | 42,089,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,000Source | — | — | 16,000Source |
| Income Taxes Paid, NetUSD | — | 6,000Source | 9,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 117,000Source | -269,000Source | 9,000Source | -366,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 8,987,000Source | 3,823,000Source | 1,483,000Source |
| Amortization of Intangible AssetsUSD | 12,000Source | 4,000Source | — | — |
| DepreciationUSD | 172,000Source | 164,000Source | 139,000Source | 64,000Source |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | 10,057,000Source | 6,824,000Source | 3,952,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 6,000Source | 9,000Source | — |
| InterestExpenseNonoperatingUSD | 2,000Source | 20,000Source | — | — |
| Investment Income, InterestUSD | 6,640,000Source | 3,737,000Source | 74,000Source | 23,000Source |
| Net Income (Loss) Attributable to ParentUSD | -77,611,000Source | -36,144,000Source | -31,632,000Source | -12,648,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -77,611,000Source | -36,144,000Source | -31,632,000Source | -12,648,000Source |
| Nonoperating Income (Expense)USD | 6,597,000Source | 3,858,000Source | 45,000Source | 173,000Source |
| Operating ExpensesUSD | 84,208,000Source | 39,996,000Source | 31,668,000Source | 12,821,000Source |
| Other Nonoperating Income (Expense)USD | -41,000Source | 141,000Source | -4,000Source | 166,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 4,500,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 7,845,000Source | 2,767,000Source | 349,000Source | 3,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | 49,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 38,831,000Source | — | — | — |
| Operating Income (Loss)USD | -84,208,000Source | -39,996,000Source | -31,668,000Source | -12,821,000Source |
| Other Nonoperating Income (Expense)USD | -41,000Source | 141,000Source | -4,000Source | 166,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -77,611,000Source | -36,138,000Source | -31,623,000Source | -12,648,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 6,000Source | 9,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -77,611,000Source | -36,144,000Source | -31,632,000Source | -12,648,000Source |
| Earnings Per Share, BasicUSD per share | -2.31Source | -1.18Source | -1.19Source | -0.63Source |
| Earnings Per Share, DilutedUSD per share | -2.31Source | -1.18Source | -1.19Source | -0.63Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 33,538,160Source | 30,538,378Source | 26,593,673Source | 19,976,596Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 33,538,160Source | 30,538,378Source | 26,593,673Source | 19,976,596Source |
| Interest Expense (non-operating)USD | 2,000Source | 20,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 12,000Source | 4,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | 6,000Source | 9,000Source | — |
| General and Administrative ExpenseUSD | — | 10,057,000Source | 6,824,000Source | 3,952,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -2,573,000Source | -2,728,000Source | -1,792,000Source | -1,097,000Source |
| Interest ExpenseUSD | — | — | 25,000Source | 16,000Source |
| Investment Income, InterestUSD | 6,640,000Source | 3,737,000Source | 74,000Source | 23,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -77,611,000Source | -36,144,000Source | -31,632,000Source | -12,648,000Source |
| Nonoperating Income (Expense)USD | 6,597,000Source | 3,858,000Source | 45,000Source | 173,000Source |
| Operating ExpensesUSD | 84,208,000Source | 39,996,000Source | 31,668,000Source | 12,821,000Source |
| Research and Development ExpenseUSD | 45,377,000Source | 29,939,000Source | 24,844,000Source | 8,869,000Source |
Filing attachments
tm2624806d1_ex99-1.htm · 6-K · 2026-09-08
Exhibit 99.1 Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027 ───────────────────────────────────────────…
Read attachment ↗tm2623018d1_ex99-1.htm · 6-K · 2026-08-13
Exhibit 99.1 Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗tm2622827d1_ex99-1.htm · 6-K · 2026-08-11
Exhibit 99.1 Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 Prescription Drug User Fee Act target action date is February 12, 2027 ──────────────────────────────────────────────────────── If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 ─────────────────────────────────────────────────────────────────────────…
Read attachment ↗